Published in Nephrol Dial Transplant on August 26, 2010
Folate-conjugated rapamycin slows progression of polycystic kidney disease. J Am Soc Nephrol (2012) 1.61
Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside. Kidney Res Clin Pract (2012) 0.75
Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin. Pflugers Arch (2013) 0.75
Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med (2006) 10.65
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med (2004) 6.52
Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant (2004) 4.27
Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int (2003) 3.90
Pure red-cell aplasia and epoetin therapy. N Engl J Med (2004) 3.49
Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet (2011) 3.15
The burden of kidney disease: improving global outcomes. Kidney Int (2004) 2.94
Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol (2004) 2.47
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med (2003) 2.47
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol (2005) 2.25
Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant (2008) 2.24
Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant (2003) 2.21
Latest US KDOQI Anaemia Guidelines update--what are the implications for Europe? Nephrol Dial Transplant (2007) 2.12
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis (2008) 2.02
Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med (2013) 2.00
Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2004) 1.93
Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol (2011) 1.84
Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant (2004) 1.83
Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2004) 1.81
Mini-peritoneal equilibration test: A simple and fast method to assess free water and small solute transport across the peritoneal membrane. Kidney Int (2005) 1.80
The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol (2008) 1.76
Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis (2003) 1.73
Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol (2010) 1.70
Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here? Nephrol Dial Transplant (2004) 1.59
Effects of ionized sodium concentrations on ultrafiltration rate in peritoneal dialysis using lactate and lactate/bicarbonate solutions. Perit Dial Int (2009) 1.57
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis (2005) 1.54
Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease. Expert Opin Drug Saf (2012) 1.51
Long-term outcome of idiopathic retroperitoneal fibrosis treated with surgical and/or medical approaches. Nephrol Dial Transplant (2006) 1.50
Improving outcomes for dialysis patients in the international Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol (2006) 1.47
Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant (2006) 1.46
Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Associations with mortality, patient characteristics, and facility practices. Am J Kidney Dis (2011) 1.45
Current Evidence in Haemodiafiltration. Blood Purif (2015) 1.41
IgA nephritis: ACE inhibitors, steroids, both or neither? Nephrol Dial Transplant (2006) 1.41
Stopping a medical research project for financial reasons. Nephrol Dial Transplant (2003) 1.40
Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol (2007) 1.40
Erythropoietic response to erythropoiesis-stimulating agents and outcome: should we give up the haemoglobin target approach? Nephrol Dial Transplant (2011) 1.39
New recommendations in the treatment of Gram-positive bacteraemia in dialysis patients. Nephrol Dial Transplant (2007) 1.39
Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int (2013) 1.35
The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant (2007) 1.35
C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol (2008) 1.34
Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrol Dial Transplant (2009) 1.24
Risk factors for cardiovascular events after successful renal transplantation. Transplantation (2008) 1.21
The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant (2004) 1.18
Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron (2002) 1.16
Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephrol (2009) 1.13
The epidemiology of end-stage renal disease in Iran in an international perspective. Nephrol Dial Transplant (2002) 1.12
Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant (2010) 1.11
Predictors of outcome in Henoch-Schönlein nephritis in children and adults. Am J Kidney Dis (2006) 1.11
Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant (2008) 1.10
The quality of dialysis water. Nephrol Dial Transplant (2003) 1.10
Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant (2010) 1.10
A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol (2006) 1.09
Kidney and liver involvement in monoclonal light chain disorders. Semin Nephrol (2002) 1.09
What we know about oxidative stress in patients with chronic kidney disease on dialysis--clinical effects, potential treatment, and prevention. Semin Dial (2011) 1.07
Outcome of peritoneal dialysis in cirrhotic patients with chronic renal failure. Am J Kidney Dis (2002) 1.07
The risk of pregnancy in patients with lupus nephritis. J Nephrol (2003) 1.07
Renal allograft thrombosis. Nephrol Dial Transplant (2009) 1.06
Biosimilars and regulatory authorities. Nephron Clin Pract (2010) 1.06
Increasing home based dialysis therapies to tackle dialysis burden around the world: a position statement on dialysis economics from the 2nd Congress of the International Society for Hemodialysis. Nephrology (Carlton) (2011) 1.06
Natural history of hepatitis B and C in renal allograft recipients. Transplantation (2005) 1.05
Depletion of clusterin in renal diseases causing nephrotic syndrome. Kidney Int (2002) 1.04
Long-term prognosis of diffuse proliferative glomerulonephritis associated with infection in adults. Nephrol Dial Transplant (2002) 1.03
Hemodialysis vascular access training and practices are key to improved access outcomes. Am J Kidney Dis (2010) 1.03
The long-term prognosis of renal transplantation in patients with lupus nephritis. Am J Kidney Dis (2005) 1.02
Pregnancy in lupus nephritis. Am J Kidney Dis (2002) 1.02
Inflammation and resistance to treatment with recombinant human erythropoietin. J Ren Nutr (2005) 1.01
Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant (2013) 1.01
The regulatory framework of biosimilars in the European Union. Drug Discov Today (2011) 0.98
Sodium balance in hemodialysis therapy. Semin Dial (2003) 0.97
Haemophagocytic syndrome--a life-threatening complication of renal transplantation. Nephrol Dial Transplant (2009) 0.96
Changes in viremia and circulating interferon-alpha during hemodialysis in hepatitis C virus-positive patients: only coincidental phenomena? Am J Kidney Dis (2003) 0.95
The role of blood volume reduction in the genesis of intradialytic hypotension. Am J Kidney Dis (2002) 0.95
Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). J Nephrol (2008) 0.95
IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine. J Nephrol (2013) 0.94
Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). J Gen Intern Med (2012) 0.94
Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation (2004) 0.93
Increased levels of circulating endothelial cells in chronic periaortitis as a marker of active disease. Kidney Int (2005) 0.93
C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant (2011) 0.93
International Study of Health Care Organization and Financing for renal replacement therapy in Italy: an evolving reality. Int J Health Care Finance Econ (2007) 0.93
COSMOS: the dialysis scenario of CKD-MBD in Europe. Nephrol Dial Transplant (2012) 0.92
Overfill of peritoneal dialysis bags as a cause of underestimation of ultrafiltration failure. Perit Dial Int (2006) 0.92
Chyluria associated with nephrotic-range proteinuria: pathophysiology, clinical picture and therapeutic options. Nephron Clin Pract (2011) 0.92
Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis (2004) 0.92
Sodium removal and sodium concentration during peritoneal dialysis: effects of three methods of sodium measurement. Nephrol Dial Transplant (2004) 0.91
Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol (2011) 0.90
Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrol Dial Transplant (2013) 0.90
High-flux versus low-flux membranes for end-stage kidney disease. Cochrane Database Syst Rev (2012) 0.90
Convection versus diffusion in dialysis: an Italian prospective multicentre study. Nephrol Dial Transplant (2003) 0.89
Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10--12 g/dl. Clin Nephrol (2012) 0.89
Dialysis adequacy today: a European perspective. Nephrol Dial Transplant (2012) 0.89
Cinacalcet for cardiovascular disease in patients undergoing dialysis. N Engl J Med (2013) 0.89
Acute post-bacterial glomerulonephritis in renal transplant patients: description of three cases and review of the literature. Am J Transplant (2004) 0.89
Influence of body mass index on the association of weight changes with mortality in hemodialysis patients. Clin J Am Soc Nephrol (2013) 0.89
Hypertension in dialysis: pathophysiology and treatment. J Nephrol (2002) 0.88
Clinical evidence on hemodiafiltration: a systematic review and a meta-analysis. Semin Dial (2014) 0.88
Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol Dial Transplant (2008) 0.88
Dialysate composition. Contrib Nephrol (2008) 0.87
Renal replacement therapy in lupus nephritis. J Nephrol (2004) 0.86